No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Blood. 2018 Jan 25;131(4):468-471. doi: 10.1182/blood-2017-08-802157. Epub 2017 Dec 11.

Authors

Rosemary E Gale¹, Teodora Popa¹, Melissa Wright², Naeem Khan³, Sylvie D Freeman³, Alan K Burnett⁴, Nigel H Russell⁵, Robert K Hills², David C Linch¹

Affiliations

¹ Department of Haematology, University College London Cancer Institute, London, United Kingdom.
² Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
³ Institute of Immunology and Immunotherapy, Department of Clinical Immunology, University of Birmingham, Birmingham, United Kingdom.
⁴ Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom; and.
⁵ Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom.

PMID: 29229596
DOI: 10.1182/blood-2017-08-802157

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aminoglycosides / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Clinical Trials as Topic
Gemtuzumab
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Polymorphism, Single Nucleotide*
Sialic Acid Binding Ig-like Lectin 3 / genetics*
Treatment Outcome
Young Adult

Substances

Aminoglycosides
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
CD33 protein, human
Sialic Acid Binding Ig-like Lectin 3
Gemtuzumab

Associated data

ISRCTN/ISRCTN17161961
ISRCTN/ISRCTN55675535

Grants and funding